Amicus Therapeutics Stock Price and Value Analysis

Amicus Therapeutics (NasdaqGM:FOLD) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Amicus Therapeutics to reach your target.

Target type

FOLD Free Cash Flow Trend

Free Cash Flow trendline for FOLD
Free Cash Flow trendline for Amicus Therapeutics

Hmm, we can't give any reliable projection for Amicus Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This company has wild ups and downs.
  • This company is not making money.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the FOLD Numbers

FOLD Price
(Amicus Therapeutics stock price per share)
$0.00
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Drug Manufacturers - General stocks
[?] Cash Yield -2.28%
[?] Free Cash Flow Jitter 79%

Insider Activity Summary

No open-market insider buys or sells are recorded in the six months to 2026-11-22.

The six months before that had 0 buys and 12 sales.

Recent Insider Activity

Open-market buys and sells reported by Amicus Therapeutics's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-03-02 Campbell Bradley L (President and CEO) Sell 22,500 $14.35
2026-01-20 Campbell Bradley L (President and CEO) Sell 75,000 $14.31
2025-12-19 Clark David Michael (Chief People Officer) Sell 25,642 $14.17
2025-12-15 Campbell Bradley L (President and CEO) Sell 77,926 $10.86
2025-12-15 Clark David Michael (Chief People Officer) Sell 25,643 $11.00
2025-12-01 Campbell Bradley L (President and CEO) Sell 14,587 $10.01
2025-11-26 Rosenberg Ellen (Chief Legal Officer) Sell 23,621 $10.00
2025-11-25 Rosenberg Ellen (Chief Legal Officer) Sell 36,000 $10.00
2025-11-24 Rosenberg Ellen (Chief Legal Officer) Sell 36,000 $10.06
2025-11-24 Campbell Bradley L (President and CEO) Sell 14,587 $10.04

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Net income was negative in all 17 fiscal years from 2009 to 2025, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$1,925 million over those years, against net income of -$2,603 million.

In 2025, net income was -$27.1 million and operating cash flow was $33.1 million, so no ratio is shown for that year.

In 2025, capital expenditures were $3.3 million, 9.9% of operating cash flow of $33.1 million, which leaves an estimated $29.8 million after capex. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 -6.6 -43.4 1.8 n/a
2010 -54.9 -14 0.4 n/a
2011 -44.4 -49.4 1.4 n/a
2012 -48.8 -33.7 4.3 n/a
2013 -59.6 -45.8 0.7 n/a
2014 -68.9 -51.7 0.2 n/a
2015 -132 -100 4.8 n/a
2016 -200 -150 6 n/a
2017 -284 -214 4.5 n/a
2018 -349 -300 6.3 n/a
2019 -356 -250 20 n/a
2020 -277 -233 3.2 n/a
2021 -250 -202 3.9 n/a
2022 -237 -167 3.8 n/a
2023 -152 -69.1 7.4 n/a
2024 -56.1 -33.9 3.6 n/a
2025 -27.1 33.1 3.3 n/a

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $64.4 million in 2009 and $634 million in 2025, a compound annual growth rate of 15.4% over 16 years.

Revenue rose 20.0% from 2024 to 2025.

Our estimated free cash flow was $28.8 million in 2025, 4.5% of revenue. In 2009 the estimated margin was negative 70.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 64.4 -45.2 -70.2%
2010 0.9 -15.1 -1635.4%
2011 21.4 -50.6 -236.2%
2012 18.4 -35.7 -194.1%
2013 0.4 -47.5 -13090.9%
2014 1.2 -53.1 -4336.7%
2016 5 -153 -3093.0%
2017 36.9 -217 -587.4%
2018 91.2 -304 -333.5%
2019 182 -259 -142.0%
2020 261 -241 -92.5%
2021 306 -210 -68.8%
2022 329 -174 -52.9%
2023 399 -76.8 -19.2%
2024 528 -38.3 -7.2%
2025 634 28.8 4.5%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $214 million against total liabilities of $676 million, or 31.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 71.1% of total assets in 2025, compared with 42.3% in 2010, an increase of 28.8 percentage points.

Stockholders equity was $274 million in 2025, compared with $64.9 million in 2010, a rise of 322.3%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 5.8% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 113 29.6 47.6 64.9
2011 69.8 25.7 40.2 29.6
2012 110 34 40.9 69.2
2013 128 43.6 81.8 45.8
2014 210 24.1 87.8 122
2015 908 69.5 561 348
2016 1,037 187 677 360
2017 627 49.1 274 353
2018 790 79.7 447 343
2019 850 143 374 476
2020 887 163 600 286
2021 905 245 598 307
2022 724 149 601 123
2023 778 247 618 160
2024 785 214 591 194
2025 950 214 676 274

Price Versus Our Estimated Value

We do not estimate a fair value for Amicus Therapeutics while its free cash flow growth is not positive, so there is no value comparison here.

Of the 17 fiscal years we can see for Amicus Therapeutics under its current filer, 1 show positive free cash flow.

Year-to-year variability in free cash flow is volatile, measured at 79%.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

We do not have a dividend yield for Amicus Therapeutics.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Amicus Therapeutics, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Amicus Therapeutics (FOLD) - - - - -
Abbott Laboratories (ABT) 178,390 38.4 2.4% 1.9% 49% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Amphastar Pharmaceuticals (AMPH) 1,205 13.0 - 0.9% 98% above
ANI Pharmaceuticals (ANIP) 1,558 13.9 - - 188% above
Bristol-Myers Squibb Company (BMY) 120,192 13.0 4.3% 1.2% 85% above
Collegium Pharmaceutical (COLL) 768 22.7 - - 155% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1178879.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 16 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: FOLD annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in FOLD

Does Amicus Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: FOLD

This example shows how we apply the Trendshare checklist to FOLD: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 0.00
    • Market cap: —
    • EPS: —
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.